ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Abstract Number: 0522
    The Incidence Rate and Risk Factors of Arrhythmias in Patients with Psoriatic Arthritis
  • Abstract Number: 0053
    The Integrin Inhibitor Cilengitide Targets CCN1-Mediated Angiogenesis and Reduces Disease Severity in a Preclinical Rheumatoid Arthritis Model
  • Abstract Number: 2037
    The Largest International Cohort Study of HA20 Reveals Novel Genetic Architecture and Age-Dependent Phenotypic Evolution
  • Abstract Number: 1450
    The Novel Digital Therapeutic Axia Improves Disease Activity, Functionality, and Quality of Life in Axial Spondyloarthritis Patients: Results from a Randomized Controlled Trial (Bechterew-App Trial)
  • Abstract Number: 0977
    The nuclear receptor DAX1 regulates WNT/β-catenin signaling to promote fibroblast activation and skin fibrosis in systemic sclerosis
  • Abstract Number: 1646
    The Obesity Paradox in Rheumatoid Arthritis: A Propensity-Matched Analysis of Mortality and Cardiovascular Outcomes
  • Abstract Number: 0428
    The OMERACT Juvenile Idiopathic Arthritis MRI Score for Active and Structural Lesions in the Sacroiliac Joints: Development and Validation in Two Longitudinal Cohorts
  • Abstract Number: 1581
    The Overall Prevalence and Associated Disease Characteristics of Calcinosis in Systemic Sclerosis: a Systematic Review and Meta-analysis
  • Abstract Number: 0440
    The Painful Truth: Non-Articular Pain’s Impact on Rheumatoid Arthritis Assessment after Initiating a new DMARD for Active Disease
  • Abstract Number: 2227
    The Paraoxonase-1 Q192R Polymorphism is Associated with Increased Risk of Incident Clinical Rheumatoid Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population
  • Abstract Number: 1127
    The Pathogenetic Role of Calcium Pyrophosphate and Basic Calcium Phosphate Crystals in Osteoarthritis: Associations with Synovial Fluid Cytokines and Clinical Indices
  • Abstract Number: 0283
    The Performance of Rule-Based Algorithms to Identify Patients With Idiopathic Inflammatory Myopathies in Electronic Health Records
  • Abstract Number: 1714
    The perimenopause period is associated with increased levels of disease activity in psoriatic arthritis
  • Abstract Number: 2385
    The Presence of Avascular Necrosis in Patients with Systemic Lupus Erythematosus Undergoing Total Knee Arthroplasty is Not Associated with Worse Outcomes
  • Abstract Number: 0120
    The Prevalence and Clinical Significance of Heritable Thrombophilia in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
  • « Previous Page
  • 1
  • …
  • 163
  • 164
  • 165
  • 166
  • 167
  • …
  • 181
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology